文献速递临床试验与 GCP真实世界研究与卫生经济医学教育与科研方法

针对妇科癌症女性的个体化与以患者为中心的新随访模式(NEMO研究)——一项随机临床试验的方案与依据

A NEw MOdel of individualized and patient-centered follow-up for women with gynecological cancer (the NEMO study)-protocol and rationale of a randomized clinical trial.
PubMed 文献 · Trials · 2023-02-01

该研究为在丹麦四家国家级妇科肿瘤中心之一开展的随机临床试验,纳入早期宫颈癌或子宫内膜癌患者。干预组接受护士主导的个体化随访,每次接触前重复使用电子患者报告结局测量(ePROM)作为对话支持工具,以患者赋能为重点;对照组接受医生主导的标准随访,不使用ePROM且不特别关注赋能。主要结局为HEI-Q问卷技能与技术子量表评估的赋能,次要结局包括癌症复发恐惧和健康相关生活质量。

要点

  • 早期妇科癌症传统随访对生存改善证据有限,且难以满足心理社会与性支持需求。
  • 干预组为护士主导的个体化随访,以ePROM为对话支持工具,重点在患者赋能。
  • 主要结局为HEI-Q问卷技能与技术子量表评估的赋能,术后3、12、18、36个月随访问卷评估。

核心结论

  • 该研究将提供早期妇科癌症随访的新信息,有助于改进未来随访方案,并了解在随访中特别关注患者赋能的影响以及如何促进患者赋能。

研究设计与样本

  • 研究设计为在丹麦四家国家级妇科肿瘤中心之一开展的临床随机试验。
  • 纳入早期宫颈癌或子宫内膜癌患者。
  • 干预组接受护士主导的个体化随访,支持患者赋能,每次接触前重复使用ePROM作为对话支持工具,随访接触主要通过电话进行。
  • 所有项目护士在项目开始前参加专门培训,均为受过良好教育且专注于妇科肿瘤的护士。
  • 对照组接受医生主导的标准随访,不使用ePROM,也不特别关注赋能。

主要发现

  • 主要结局为使用HEI-Q问卷技能与技术子量表评估的赋能。
  • 次要结局包括癌症复发恐惧、健康相关生活质量以及HEI-Q的其余子量表。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Follow-up programs for gynecological cancer patients are currently under revision. There is limited evidence that traditional follow-up and clinical examinations improve survival in an early-stage gynecological setting. Further, traditional follow-up programs fail to accommodate the patient's need for psychosocial and sexual supportive care and to actively involve patients and their relatives in the follow-up process. Individualized programs may replace traditional routine follow-up with fixed intervals and length. Focusing on alarm-symptoms and self-reporting may ensure detection of recurrence while allowing a continuous attention to the patient's well-being and return to daily life. In this study, a nurse-led, individualized, and need-based intervention with a specific focus on patient empowerment is tested against a standard physician-led model primarily focusing on the detection of recurrence. METHODS: The study is designed as a clinical, randomized trial conducted in one of four national onco-gynecological centers in Denmark. Patients with early-stage cervical or endometrial cancer are eligible for inclusion. The intervention group undergoes individualized, nurse-led follow-up supporting patient empowerment including repeated use of electronic patient-reported outcome measures (ePROMs) before each contact as a dialogue support tool. The follow-up contacts are mainly conducted by telephone. All project nurses attended a special training program before project start and are all well-educated and dedicated onco-gynecological nurses. The control group receives standard, physician-led, follow-up without use of ePROMs or specific focus on empowerment. The effect of the intervention is evaluated by questionnaires completed by patients at baseline (3 months after surgery) and 12, 18, and 36 months after surgery. Outcomes include empowerment using the Skill and technique subscale of the HEI-Q questionnaire as the primary outcome while fear of cancer recurrence and health-related quality of life as well as the remaining subscales of the HEI-Q represent secondary outcomes. Data is collected by use of the REDCap technology, which also provides a customized visual support function for the dialogue tool. DISCUSSION: This study will provide new information about follow-up in early-stage gynecological cancer settings and thereby contribute to improvement of future follow-up programs. Importantly, the study will provide knowledge about the impact of specific focus on patient empowerment in follow-up programs and, further, how to facilitate empowerment among patients. TRIAL REGISTRATION: The study is registered at clinicaltrials.gov: ID no. NCT03838861. Registered on 6 February 2019. Protocol version 2, issue date 21 November 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Bergholdt SH, Hansen DG, Johnsen AT, et al. A NEw MOdel of individualized and patient-centered follow-up for women with gynecological cancer (the NEMO study)-protocol and rationale of a randomized clinical trial. Trials. 2023. PMID: 36726187. doi:10.1186/s13063-022-07022-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。